292 related articles for article (PubMed ID: 21940738)
1. Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile.
Hägerstrand D; He X; Bradic Lindh M; Hoefs S; Hesselager G; Ostman A; Nistér M
Neuro Oncol; 2011 Nov; 13(11):1178-91. PubMed ID: 21940738
[TBL] [Abstract][Full Text] [Related]
2. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
3. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
[TBL] [Abstract][Full Text] [Related]
4. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
[TBL] [Abstract][Full Text] [Related]
5. SFRP2 induces a mesenchymal subtype transition by suppression of SOX2 in glioblastoma.
Guo M; Goudarzi KM; Abedi S; Pieber M; Sjöberg E; Behnan J; Zhang XM; Harris RA; Bartek J; Lindström MS; Nistér M; Hägerstrand D
Oncogene; 2021 Aug; 40(32):5066-5080. PubMed ID: 34021259
[TBL] [Abstract][Full Text] [Related]
6. Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor.
Iwata R; Maruyama M; Ito T; Nakano Y; Kanemura Y; Koike T; Oe S; Yoshimura K; Nonaka M; Nomura S; Sugimoto T; Yamada H; Asai A
Med Mol Morphol; 2017 Dec; 50(4):211-219. PubMed ID: 28516286
[TBL] [Abstract][Full Text] [Related]
7. Essential role of METTL3-mediated m
Visvanathan A; Patil V; Arora A; Hegde AS; Arivazhagan A; Santosh V; Somasundaram K
Oncogene; 2018 Jan; 37(4):522-533. PubMed ID: 28991227
[TBL] [Abstract][Full Text] [Related]
8. FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2.
Lee Y; Kim KH; Kim DG; Cho HJ; Kim Y; Rheey J; Shin K; Seo YJ; Choi YS; Lee JI; Lee J; Joo KM; Nam DH
PLoS One; 2015; 10(10):e0137703. PubMed ID: 26444992
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.
Carra E; Barbieri F; Marubbi D; Pattarozzi A; Favoni RE; Florio T; Daga A
Cell Cycle; 2013 Feb; 12(3):491-500. PubMed ID: 23324350
[TBL] [Abstract][Full Text] [Related]
10. ER stress and UPR activation in glioblastoma: identification of a noncanonical PERK mechanism regulating GBM stem cells through SOX2 modulation.
Peñaranda-Fajardo NM; Meijer C; Liang Y; Dijkstra BM; Aguirre-Gamboa R; den Dunnen WFA; Kruyt FAE
Cell Death Dis; 2019 Sep; 10(10):690. PubMed ID: 31534165
[TBL] [Abstract][Full Text] [Related]
11. Sox2 promotes malignancy in glioblastoma by regulating plasticity and astrocytic differentiation.
Berezovsky AD; Poisson LM; Cherba D; Webb CP; Transou AD; Lemke NW; Hong X; Hasselbach LA; Irtenkauf SM; Mikkelsen T; deCarvalho AC
Neoplasia; 2014 Mar; 16(3):193-206, 206.e19-25. PubMed ID: 24726753
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
13. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
Liu Q; Nguyen DH; Dong Q; Shitaku P; Chung K; Liu OY; Tso JL; Liu JY; Konkankit V; Cloughesy TF; Mischel PS; Lane TF; Liau LM; Nelson SF; Tso CL
J Neurooncol; 2009 Aug; 94(1):1-19. PubMed ID: 19468690
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance.
Garros-Regulez L; Aldaz P; Arrizabalaga O; Moncho-Amor V; Carrasco-Garcia E; Manterola L; Moreno-Cugnon L; Barrena C; Villanua J; Ruiz I; Pollard S; Lovell-Badge R; Sampron N; Garcia I; Matheu A
Expert Opin Ther Targets; 2016; 20(4):393-405. PubMed ID: 26878385
[TBL] [Abstract][Full Text] [Related]
15. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
16. Oncogenes Activate an Autonomous Transcriptional Regulatory Circuit That Drives Glioblastoma.
Singh DK; Kollipara RK; Vemireddy V; Yang XL; Sun Y; Regmi N; Klingler S; Hatanpaa KJ; Raisanen J; Cho SK; Sirasanagandla S; Nannepaga S; Piccirillo S; Mashimo T; Wang S; Humphries CG; Mickey B; Maher EA; Zheng H; Kim RS; Kittler R; Bachoo RM
Cell Rep; 2017 Jan; 18(4):961-976. PubMed ID: 28122245
[TBL] [Abstract][Full Text] [Related]
17. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.
Fan X; Khaki L; Zhu TS; Soules ME; Talsma CE; Gul N; Koh C; Zhang J; Li YM; Maciaczyk J; Nikkhah G; Dimeco F; Piccirillo S; Vescovi AL; Eberhart CG
Stem Cells; 2010 Jan; 28(1):5-16. PubMed ID: 19904829
[TBL] [Abstract][Full Text] [Related]
18. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
19. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
[TBL] [Abstract][Full Text] [Related]
20. Heat Shock Factor 1 Depletion Sensitizes A172 Glioblastoma Cells to Temozolomide via Suppression of Cancer Stem Cell-Like Properties.
Im CN; Yun HH; Lee JH
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
